CLRB · Cellectar Biosciences, Inc.
$2.40
-0.07 (-2.83%)
At close · Jul 24
Going-concern doubt
— flagged May 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These uncertainties raise substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed May 14, 2026
Market Cap
$19.26M
Shares
7.99M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$2.47
Open$2.51
Day$2.42–2.58
52W$2.20–6.52
Avg vol 30d115K
Short int199K · 2.5% float · 1.7d
Short vol14%
Last earningsMay 14, 2026
DataJan 2020–Jul 2026
Filing10-Q · May 14
Up next
Next earnings call
Aug 14, 2026
Est · unconfirmed
· in 3 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 14, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 18.6 · elevated
Equity put/call 0.79
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−22%
below
Price vs 50-day avg
−9%
below
RSI (14)
41
neutral
MACD trend
Negative
52-week position
6%
near low
Momentum
relative strength
1-month return
−1%
trailing
6-month return
−24%
trailing
YTD return
−16%
this year
Relative strength
−30%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $3 › 200d $3 — 200d above 50d
Institutional flow
Accumulating
2 of 19 funds reported for Jun 30 · net +3.0K sh shares
Insider flow
Accumulating
Net +$50.0K over 90 days · 0% sells
Short interest
Rising
2.50% of float · ▲ +2.6% MoM · 1.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
19 holders — near 1-yr low, contrarian setup
Squeeze score
53
elevated · 0–100
Fundamentals
EPS growth
+80%
Y/Y
Free cash flow
$-23.1M
Balance sheet
$12.9M
net cash
Quant / Vol
risk profile
Volatility
82%
annualized · 1-yr
Max drawdown
−64%
past year
ATR
7.3%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−22%
Bearish
Price vs 50-day avg
−9%
Bearish
RSI (14)
41
Neutral
MACD trend
Negative
Bearish
52-week position
6%
Bearish
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $3 › 200d $3 — 200d above 50d
Institutional flow
Accumulating
2 of 19 funds reported for Jun 30 · net +3.0K sh shares
Insider flow
Accumulating
Net +$50.0K over 90 days · 0% sells
Short interest
Rising
2.50% of float · ▲ +2.6% MoM · 1.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
19 holders — near 1-yr low, contrarian setup
Price context
position in its 52-week range
52-wk low $2
Now $2 · 6%
52-wk high $7
vs 200-day avg -22%
vs 50-day avg -9%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CLRB
this stock
Cellectar Biosciences, Inc.
|
$19.26M | -16.3% | — | — | 2.5% |
|
ONC
BeOne Medicines Ltd.
|
$471.01B | +7.6% | +22179.2% | 958.5 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$121.16B | +4.4% | +46.2% | 28.3 | 2.0% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$68.78B | -15.4% | +20.8% | 16.0 | 3.3% |
|
ARGX
Argenx SE
|
$57.44B | +9.9% | — | — | 2.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CLRB | -4.3% | -0.8% | -23.8% | -11.2% | -16.3% |
| SPY | -1.7% | +0.7% | +6.4% | -1.2% | +8.3% |
| vs SPY | -2.6% | -1.5% | -30.1% | -10.0% | -24.5% |